The following is a summary of "Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines," ...

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 ...

Due to the ease of nanobody engineering, they can be employed in three nanobody-based therapeutic platforms: platform A, receptor antagonists to interfere with or block the activation of a certain ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have earned a consensus recommendation of “Buy” from ...

Investment analysts at Wedbush cut their Q1 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a ...

(formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully ...

Porosome Therapeutics, Inc. announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA).

The platform specializes in highly specific nanobody-mediated targeted therapies that greatly reduce drug side effects. Porosome Therapeutics, Inc. announced the Orphan Drug Designation of its ...